ANCA相关血管炎缓解期延长治疗的随机对照试验
一项前瞻性随机试验比较了抗中性粒细胞胞浆抗体(ANCA)相关血管炎(AAV)患者维持免疫抑制治疗两种不同时长的复发预防效果。患者随机接受继续硫唑嘌呤/泼尼松龙至诊断后48个月或24个月时撤药,主要终点为随机化至诊断后48个月的复发风险。结果显示撤药组复发率显著高于继续治疗组(63% vs 22%),延长治疗降低复发风险并改善肾脏生存。
要点
- 延长硫唑嘌呤/泼尼松龙维持治疗至48个月可显著降低AAV复发风险。
- 撤药组复发率63%,继续治疗组22%,OR 5.96(95%CI 2.58-13.77)。
- 随机化时ANCA阳性与复发风险相关,继续治疗组严重不良事件更多但终末期肾病更少。
核心结论
- 延长硫唑嘌呤/泼尼松龙维持治疗至诊断后48个月可降低AAV患者复发风险并改善肾脏生存。
研究设计与样本
- 前瞻性随机对照试验,纳入诊断后18-24个月且处于稳定缓解的AAV患者,1:1随机分为继续治疗组(硫唑嘌呤/泼尼松龙至48个月)和撤药组(24个月时撤药)。
主要发现
- 撤药组复发率63%,继续治疗组22%,差异显著(p<0.0001,OR 5.96,95%CI 2.58-13.77)。
- 随机化时ANCA阳性与复发风险相关(51% vs 29%,p=0.017,OR 2.57,95%CI 1.16-5.68)。
- 肾功能、ANCA特异性、血管炎类型和年龄不能预测复发。
- 继续治疗组严重不良事件更多(9 vs 3例),但终末期肾病更少(0 vs 4例),患者生存无差异。
关键数值与推荐
- 入组时中位血清肌酐116 μmol/L(范围58-372),53%为ANCA阳性。
临床怎么用
- 对于诊断后18-24个月处于稳定缓解的AAV患者,延长硫唑嘌呤/泼尼松龙维持治疗至48个月可考虑用于降低复发和改善肾脏预后。
- 随机化时ANCA阳性提示复发风险较高,可能支持延长治疗决策。
局限性
- 严重不良事件在继续治疗组更常见,需权衡获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A prospective randomised trial to compare two different durations of maintenance immunosuppressive therapy for the prevention of relapse in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). METHODS: Patients with AAV were recruited 18-24 months after diagnosis if they were in stable remission after cyclophosphamide/prednisolone-based induction followed by azathioprine/prednisolone maintenance therapy. They were randomised (1:1) to receive continued azathioprine/prednisolone to 48 months from diagnosis (continuation group) or to withdraw azathioprine/prednisolone by 24 months (withdrawal group). The primary endpoint was the relapse risk, from randomisation to 48 months from diagnosis. RESULTS: One hundred and seventeen patients were randomised and 110 remained to the trial end. At entry, median serum creatinine was 116 μmol/L (range 58-372), 53% were ANCA positive. The percentage of patients presenting with relapse was higher in the withdrawal than in the continuation treatment group (63% vs 22%, p<0.0001, OR 5.96, 95% CI 2.58 to 13.77). ANCA positivity at randomisation was associated with relapse risk (51% vs 29%, p=0.017, OR 2.57, 95% CI 1.16 to 5.68). Renal function, ANCA specificity, vasculitis type and age were not predictive of relapse. Severe adverse events were more frequent in the continuation than withdrawal groups (nine vs three events), but the continuation group had better renal outcome (0 vs 4 cases of end-stage renal disease), with no difference in patient survival. CONCLUSIONS: Prolonged remission maintenance therapy with azathioprine/prednisolone, beyond 24 months after diagnosis reduces relapse risk out to 48 months and improves renal survival in AAV. TRIAL REGISTRATION NUMBER: ISRCTN13739474.
引用
- Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017. PMID: 28546260. doi:10.1136/annrheumdis-2017-211123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。